Pediatric dosing expected to begin in Q4 2025Pivotal cohort expected to begin enrolling in Q1 2026BLA submission anticipated in early 2028Part A ...

Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor 1 Filing ...

Each year during Hispanic Heritage Month, huge celebrations can be expected across the U.S. to showcase the diversity and ...

European expansion in September across Georgia, Italy, Lithuania, Poland, Romania, Spain, and US13 subjects recruited (treated, enrolled, or ...

Hayden Homes just received a major national honor. It ranked #3 on Fortune Magazine's 2025 Best Workplaces in Construction list. It made that list for the 2nd time. The company also ranked #21 on ...

Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE ...

Despite psychedelics’ roots in Indigenous and minoritised communities, clinical trials overwhelmingly centre White ...

Enlicitide is an investigational, oral, PCSK9 inhibitor designed to bind to PSCK9, a key regulator of cholesterol, and block its interaction with LDL receptors.

Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event ...